X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27855) 27855
Book Review (4082) 4082
Publication (2029) 2029
Book Chapter (206) 206
Conference Proceeding (123) 123
Dissertation (65) 65
Government Document (41) 41
Magazine Article (38) 38
Book / eBook (14) 14
Newsletter (12) 12
Web Resource (11) 11
Streaming Video (5) 5
Data Set (2) 2
Newspaper Article (2) 2
Paper (2) 2
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22827) 22827
humans (22815) 22815
male (8255) 8255
hematology (8210) 8210
oncology (8067) 8067
female (7697) 7697
adult (6625) 6625
chronic myelogenous leukemia (6602) 6602
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6442) 6442
middle aged (6068) 6068
leukemia, myelogenous, chronic, bcr-abl positive - genetics (5809) 5809
imatinib mesylate (5253) 5253
chronic myeloid-leukemia (4979) 4979
animals (4872) 4872
leukemia, myelogenous, chronic, bcr-abl positive - pathology (4793) 4793
bcr-abl (4607) 4607
chronic myeloid leukemia (4311) 4311
leukemia (4072) 4072
benzamides (3858) 3858
fusion proteins, bcr-abl - genetics (3796) 3796
aged (3770) 3770
antineoplastic agents - therapeutic use (3281) 3281
leukemia, myelogenous, chronic, bcr-abl positive - therapy (3225) 3225
mice (3190) 3190
imatinib (3078) 3078
pyrimidines - therapeutic use (2998) 2998
cancer (2804) 2804
biochemistry & molecular biology (2610) 2610
piperazines - therapeutic use (2578) 2578
adolescent (2544) 2544
cell biology (2314) 2314
abridged index medicus (2254) 2254
cml (2213) 2213
apoptosis (2190) 2190
treatment outcome (2118) 2118
philadelphia chromosome (1980) 1980
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (1962) 1962
hemic and lymphatic diseases (1938) 1938
protein kinase inhibitors - therapeutic use (1931) 1931
mutation (1929) 1929
phosphorylation (1877) 1877
tyrosine kinase (1817) 1817
research (1783) 1783
pyrimidines - pharmacology (1781) 1781
antineoplastic agents - pharmacology (1733) 1733
philadelphia-chromosome (1661) 1661
fusion proteins, bcr-abl - metabolism (1644) 1644
c-abl (1616) 1616
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (1604) 1604
prognosis (1597) 1597
cell line, tumor (1570) 1570
therapy (1519) 1519
abl tyrosine kinase (1514) 1514
child (1505) 1505
acute lymphoblastic-leukemia (1503) 1503
piperazines - pharmacology (1491) 1491
expression (1483) 1483
protein-tyrosine kinases - antagonists & inhibitors (1456) 1456
k562 cells (1455) 1455
cells (1436) 1436
signal transduction (1434) 1434
dasatinib (1414) 1414
tumor cells, cultured (1385) 1385
molecular sequence data (1339) 1339
bone marrow transplantation (1322) 1322
genetic aspects (1300) 1300
transplantation (1289) 1289
care and treatment (1284) 1284
protein kinase inhibitors - pharmacology (1279) 1279
apoptosis - drug effects (1270) 1270
proteins (1263) 1263
analysis (1246) 1246
tyrosine (1244) 1244
genetics & heredity (1231) 1231
leukemia, myelogenous, chronic, bcr-abl positive - complications (1183) 1183
drug resistance, neoplasm (1180) 1180
cell line (1173) 1173
aged, 80 and over (1165) 1165
polymerase chain reaction (1150) 1150
immunology (1129) 1129
base sequence (1119) 1119
activation (1107) 1107
abl (1095) 1095
young adult (1083) 1083
leukemia, myelogenous, chronic, bcr-abl positive (1073) 1073
leukemia, myelogenous, chronic, bcr-abl positive - blood (1068) 1068
leukemia, myelogenous, chronic, bcr-abl positive - mortality (1067) 1067
blast crisis (1061) 1061
resistance (1055) 1055
time factors (1046) 1046
transplantation, homologous (1036) 1036
pharmacology & pharmacy (1029) 1029
kinases (1028) 1028
tyrosine kinase inhibitor (1024) 1024
leukemia, myelogenous, chronic, bcr-abl positive - immunology (1008) 1008
gene expression (1001) 1001
article (986) 986
translocation, genetic (983) 983
remission induction (978) 978
gene (971) 971
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (8) 8
Gerstein Science - Stacks (7) 7
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Credit Valley Hospital - Stacks (1) 1
Robarts - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
Trinity College (John W Graham) - Stacks (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (25434) 25434
Chinese (687) 687
Japanese (620) 620
French (255) 255
German (252) 252
Russian (245) 245
Spanish (221) 221
Polish (125) 125
Italian (75) 75
Czech (51) 51
Hungarian (50) 50
Portuguese (37) 37
Danish (22) 22
Korean (22) 22
Swedish (17) 17
Dutch (15) 15
Romanian (12) 12
Ukrainian (11) 11
Norwegian (9) 9
Serbian (8) 8
Turkish (8) 8
Croatian (7) 7
Hebrew (7) 7
Slovak (7) 7
Finnish (6) 6
Bulgarian (3) 3
Persian (2) 2
Indonesian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2013, ISBN 1615190678, xiii, 303 p., [8] p. of plates
Book
Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7541, pp. 102 - 105
The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of adult acute lymphoblastic leukaemia(1). Introduction of ABL1... 
MECHANISM | POSITIVE LEUKEMIA | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | RESISTANCE | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | KINASE INHIBITOR | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | T315I MUTANT | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Molecular Conformation | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Protein Kinase Inhibitors - chemistry | Angiogenesis Inhibitors - therapeutic use | Imidazoles - therapeutic use | Phosphorylation - drug effects | Fusion Proteins, bcr-abl - chemistry | Cell Line | Proto-Oncogene Proteins c-abl - genetics | Indazoles - chemistry | Crystallization | Proto-Oncogene Proteins c-abl - chemistry | Angiogenesis Inhibitors - pharmacology | Models, Molecular | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Imidazoles - pharmacology | Drug Repositioning | Indazoles - pharmacology | Drug Resistance, Neoplasm - genetics | Fusion Proteins, bcr-abl - genetics | Vascular Endothelial Growth Factor Receptor-2 - chemistry | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Binding | Proto-Oncogene Proteins c-abl - metabolism | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Kidney Neoplasms - drug therapy | Fusion Proteins, bcr-abl - metabolism | Indazoles - therapeutic use | Angiogenesis Inhibitors - chemistry | Drug Screening Assays, Antitumor | Axitinib | Genetic aspects | Research | Gene mutations | Drug resistance | Analysis | Phosphorylation | Inhibitor drugs | Leukemia | Bone marrow | Mutation | Kinases | Drug dosages | Patients | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2017, Volume 543, Issue 7647, pp. 733 - 737
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 841 - 851
Summary Background Nilotinib has shown greater efficacy than imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid... 
Hematology, Oncology and Palliative Medicine | CHRONIC MYELOGENOUS LEUKEMIA | HALF | THERAPY | ONCOLOGY | MOLECULAR RESPONSES | RECOMMENDATIONS | HARMONIZING CURRENT METHODOLOGY | TYROSINE KINASE INHIBITOR | DISCONTINUATION | BCR-ABL TRANSCRIPTS | Piperazines - administration & dosage | Singapore | Protein-Tyrosine Kinases - metabolism | United States | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Protein-Tyrosine Kinases - genetics | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Brazil | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Philadelphia Chromosome | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Drug Administration Schedule | Administration, Oral | Pyrimidines - administration & dosage | Europe | Kaplan-Meier Estimate | Survival Rate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Piperazines - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Benzamides | Australia | Fusion Proteins, bcr-abl - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Antineoplastic agents | Product development | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1029 - 1035
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 03/2013, Volume 288, Issue 9, pp. 6116 - 6129
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 424 - 430
Journal Article
Cancer Letters, ISSN 0304-3835, 2015, Volume 360, Issue 2, pp. 245 - 256
Highlights • MiR-424 expression is low in CML cell lines and patient samples at time of diagnosis. • Using bioinformatics we revealed a conserved miR-424... 
Hematology, Oncology and Palliative Medicine | BCR–ABL | Imatinib | miR-424 | CML | Apoptosis | MiR-424 | BCR-ABL | EXPRESSION PROFILES | MIR-16 FAMILY | CHRONIC MYELOID-LEUKEMIA | TYROSINE KINASE INHIBITORS | SMALL INTERFERING RNA | LYMPHOCYTIC-LEUKEMIA | ONCOLOGY | ENDOTHELIAL-CELLS | GENE-EXPRESSION | CYCLE PROGRESSION | MICRORNA EXPRESSION | Apoptosis - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Apoptosis - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy | Fusion Proteins, bcr-abl - biosynthesis | Transfection | Base Sequence | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Cell Growth Processes - genetics | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Cell Growth Processes - drug effects | MicroRNAs - administration & dosage | Down-Regulation | MicroRNAs - biosynthesis | Combined Modality Therapy | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | K562 Cells | HL-60 Cells | MicroRNAs - genetics | HeLa Cells | Fusion Proteins, bcr-abl - metabolism | Antimitotic agents | Antineoplastic agents | Cell growth | Kinases | Leukemia | Cell cycle | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 22, pp. 2075 - 2088
Ponatinib was developed to overcome resistance to the tyrosine kinase inhibitors used to treat leukemias that are positive for the Philadelphia chromosome. In... 
CHRONIC MYELOGENOUS LEUKEMIA | MEDICINE, GENERAL & INTERNAL | RESPONSE CRITERIA | KINASE DOMAIN MUTATIONS | DIAGNOSED CHRONIC-PHASE | TYROSINE KINASE | INTERNATIONAL-WORKING-GROUP | FOLLOW-UP | CLINICAL RESISTANCE | BCR-ABL INHIBITOR | CHRONIC MYELOID-LEUKEMIA | Amylases - blood | Lipase - blood | Follow-Up Studies | Humans | Middle Aged | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Imidazoles - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Drug Resistance, Neoplasm | Male | Structure-Activity Relationship | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Protein-Tyrosine Kinases - genetics | Antineoplastic Agents - adverse effects | Pyridazines - administration & dosage | Aged, 80 and over | Adult | Female | Pyridazines - adverse effects | Imidazoles - adverse effects | Antineoplastic Agents - chemistry | Pancreatitis - chemically induced | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Mutation | Protein-Tyrosine Kinases - antagonists & inhibitors | Patient outcomes | BCR-ABL tyrosine kinase inhibitors | Dosage and administration | Genetic aspects | Acute lymphocytic leukemia | Research | Drug therapy | Tyrosine | BCR protein | Acute lymphatic leukemia | Myeloid leukemia | Leukemia | Pancreatitis | Abl protein | Chronic myeloid leukemia | Lymphatic leukemia | Lipase | Kinases | Philadelphia chromosome | Proteins | Myelosuppression | Fusion protein | Protein-tyrosine kinase | Binding sites | Index Medicus | Abridged Index Medicus
Journal Article